J7620 HCPCS Level II code: Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme
J7620 is the HCPCS code for “Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7620Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme
Short description: Albuterol ipratrop non-comp
HCPCS · United States
Notes for J7620
As CMS prints them, with any note J7620 takes from the headings above it.
Note
- CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).
Medicare details
The indicators CMS publishes with J7620 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2006
Where J7620 sits
- 1J codesDrugs administered other than orally
- 2Active code J7620Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7620 mean?
J7620 is the HCPCS code for “Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7620?
CMS lists J7620’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7620
All J codesJ7610Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mgJ7611Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mgJ7612Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mgJ7613Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mgJ7614Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mgJ7615Levalbuterol, inhalation solution, compounded product, administered through dme, unit dose, 0.5 mgJ7622Beclomethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7624Betamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7626Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mgJ7627Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mgJ7628Bitolterol mesylate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7629Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram